Retatrutide Research
What Is Retatrutide? Complete Research Overview
Reviewed by our laboratory team · Last updated 2026-07-03
Retatrutide (LY3437943) is an investigational triple-receptor agonist peptide developed by Eli Lilly. It binds and activates the GIP, GLP-1, and glucagon receptors simultaneously, making it the first triple-agonist incretin currently progressing through the Phase 3 TRIUMPH clinical trial programme.
Key facts
- Chemical name
- LY3437943 (Retatrutide)
- Class
- Triple receptor agonist (GIP/GLP-1/Glucagon)
- Molecular weight
- ~4,731 Da
- Developer
- Eli Lilly and Company
- Status
- Investigational — Phase 3 (TRIUMPH programme)
- Approval
- Not approved by FDA, EMA, or MHRA
What is retatrutide chemically?
Retatrutide is a 39-amino-acid synthetic peptide analogue derived from the GIP scaffold, engineered with fatty-acid conjugation to extend its plasma half-life. It is a single-molecule triple agonist — one peptide chain that binds three distinct incretin family receptors at physiologically relevant concentrations.
Who developed retatrutide?
Retatrutide is being developed by Eli Lilly and Company under the internal code LY3437943. The programme sits alongside Lilly's earlier incretin work on dulaglutide (Trulicity) and tirzepatide (Mounjaro / Zepbound), and represents the next generation beyond dual GIP/GLP-1 agonism.
Research material referenced
Retatrutide 10mg — third-party HPLC tested
What is its regulatory status?
As of 2026 retatrutide is an investigational compound. It has not received marketing authorisation from the FDA, EMA, or MHRA, and is available only within clinical-trial and research settings. It is progressing through the Phase 3 TRIUMPH programme.
Why is it studied?
Published Phase 2 data in the New England Journal of Medicine (Jastreboff et al., 2023) reported the largest weight reductions observed to date for any single-molecule incretin agonist. This has made retatrutide a widely referenced compound in metabolic pharmacology research literature.
Extended research context
The Retatrutide Research deep dive
Deep dive: how the triple-agonist scaffold was engineered
Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance — the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.
The TRIUMPH Phase 3 programme in context
TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator — FDA, EMA, or MHRA — has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.
How retatrutide differs from tirzepatide and semaglutide at the mechanism level
Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press — but the pharmacology is more nuanced than the label implies.
Research applications
- ▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
- ▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
- ▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
- ▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
- ▸Reference material for teaching incretin pharmacology in university-level courses
Handling checklist
- ✓Store lyophilised vials at −20 °C; protect from light and humidity
- ✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
- ✓Once reconstituted, store at 2–8 °C and use within 28 days
- ✓Verify batch CoA — HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
- ✓Do not administer to humans or animals — research use only
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Confusing retatrutide with tirzepatide in supplier catalogues
Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.
✗ Using tap or filtered water for reconstitution
Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water — never lab DI water.
✗ Storing reconstituted solution at room temperature
Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Is retatrutide the same molecule as LY3437943?
- What is the correct spelling: retatrutide or retatrutid?
- Is retatrutide a GLP-1 drug?
- Which company makes retatrutide?
- When will retatrutide be FDA approved?
- Is retatrutide legal in the UK?
Frequently asked questions
- Is retatrutide the same as tirzepatide?
- No. Tirzepatide is a dual GIP/GLP-1 agonist; retatrutide adds glucagon-receptor activity, making it a triple agonist.
- Is retatrutide approved anywhere?
- No. As of 2026 retatrutide has not been approved by any regulator worldwide. It remains an investigational compound.
- What does LY3437943 mean?
- It is Eli Lilly's internal development code for retatrutide, used in trial registrations and published research.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab (external, rel="nofollow").
- RefJastreboff et al., NEJM 2023nejm.org
- TrialClinicalTrials.gov — TRIUMPH programmeclinicaltrials.gov
- PubChemPubChem: Retatrutidepubchem.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05869903) — Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05882045) — Retatrutide in obesity + T2DMclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05936151) — Retatrutide + established CVDclinicaltrials.gov
- PubMedJastreboff et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity — NEJM 2023 (PMID 37356472)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock et al., Retatrutide in adults with T2D — Lancet 2023 (PMID 37356473)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Retatrutide (CID 156588324)pubchem.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
More Retatrutide Research articles
- Retatrutide Peptide: Structure, Sequence and MechanismRetatrutide peptide structure, 39-amino-acid sequence, fatty-acid conjugation and the receptor-binding mechanism at GIP, GLP-1 and glucagon receptors.
- What Does "Reta" Mean? The Retatrutide Abbreviation'Reta' is a shorthand for retatrutide (LY3437943), Eli Lilly's investigational triple-agonist peptide. Origin of the name and INN naming conventions explained.
- Reta Peptides Explained'Reta peptides' refers to retatrutide (LY3437943), Eli Lilly's investigational triple GIP/GLP-1/glucagon receptor agonist peptide. Class and context explained.
- Retatrutide vs Semaglutide vs Tirzepatide: Receptor ComparisonCompare retatrutide, semaglutide and tirzepatide by receptor targets, molecular structure, developer and regulatory status. Peer-reviewed research overview.
- Is Retatrutide FDA Approved? Regulatory Status ExplainedRetatrutide is not FDA approved. It is an investigational peptide in the Phase 3 TRIUMPH programme. Current EMA, MHRA and FDA regulatory status explained.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- GHK-Cu (Copper Peptide)What Is GHK-Cu? Copper Peptide Research OverviewGHK-Cu is a naturally occurring copper-binding tripeptide consisting of glycine, histidine, and lysine complexed with a copper(II) ion. It was discovered in 1973 by Loren Pickart and is widely studied in the peer-reviewed literature for its roles in gene expression, wound repair models, and extracellular matrix biology.
- TB-500 (Thymosin β4 fragment)What Is TB-500? Research OverviewTB-500 is a synthetic peptide corresponding to the active actin-binding region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-residue protein. It is studied in the peer-reviewed literature primarily for actin sequestration, cell migration, and angiogenesis in in vitro and animal models.
- BPC-157 (Pentadecapeptide)What Is BPC-157? Research OverviewBPC-157 is a synthetic 15-amino-acid peptide (pentadecapeptide) derived from a partial sequence of a protein isolated from human gastric juice. It has been studied primarily by researchers at the University of Zagreb since the 1990s for effects on tissue repair, angiogenesis, and gastrointestinal models.
- CJC-1295 & IpamorelinWhat Is CJC-1295? Research OverviewCJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue originally developed by ConjuChem. It exists in two research forms: with Drug Affinity Complex (DAC), which extends half-life via albumin binding, and without DAC (also called Modified GRF 1-29), which has a much shorter half-life.
- Peptide ReferenceWhat Are Peptides? Complete GuidePeptides are short chains of amino acids connected by peptide (amide) bonds. Typically fewer than 50 residues, they occupy the middle ground between single amino acids and proteins. Peptides serve as hormones, signalling molecules, structural fragments, and — increasingly — as research and therapeutic targets.
- Bacteriostatic WaterWhat Is Bacteriostatic Water?Bacteriostatic water is sterile water containing 0.9% benzyl alcohol as a bacteriostatic preservative. The benzyl alcohol inhibits bacterial growth after the vial's initial puncture, making the same vial suitable for repeated withdrawal in research handling. It is not the same as plain sterile water.